Introduction
Understanding the crosstalk between cellular signal pathways is critical to decipher the regulation of cellular physiology. Intracellular calcium concentrations are tightly regulated and are altered during transmembrane signaling events, such as those stimulated by growth factors, and also in response to cellular injury or stress (Berridge et al., 1998; Bukau and Horwich, 1998; Zwick et al., 1999) . We have identi®ed an inhibitor of calcium in¯ux in nonexcitable cells, CAI (Felder et al., 1991; Gusovsky et al., 1993; Kohn et al., 1994a) . Exposure to CAI causes tumor and endothelial cell cytostasis and inhibits cell attachment, migration, and angiogenesis and tumorigenesis in vitro and in vivo (Kohn et al., 1992 (Kohn et al., , 1994a (Kohn et al., ,b, 1995 Kohn and Liotta, 1990) . We hypothesized that continuous exposure to CAI by altering stimulated and basal intracellular calcium concentrations would stress the tumor cells. This would then either stimulate a stress recovery response or alter regulation or expression of proteins required for calcium activation pathways, such as the phospholipases. Activated phospholipases C produce inositol trisphosphate, a potent second messenger inducing internal calcium release and subsequent transmembrane calcium in¯ux (Berridge et al., 1998) . We developed a stress model in which tumor cell sublines were isolated after long term continuous exposure to increasing concentrations of CAI. We now report cloning of CAIR-1, CAI stressed-1, a protein nearly identical to BAG-3 (Takayama et al., 1999) from CAI-stressed cells, and demonstrate novel regulation and function of CAIR-1/BAG-3.
BAG-3 was cloned from a screen for homologs of the bcl-2 binding protein BAG-1 (bcl-2-associated athanogene) family (Takayama et al., 1995 (Takayama et al., , 1999 . BAG-1 was identi®ed in a screen for bcl-2 binding proteins and has been shown to inhibit apoptosis and promote tumorigenesis (Stuart et al., 1998; Takayama et al., 1995 Takayama et al., , 1997 . Recent homology cloning identi®ed fragments of at least four other BAG family members, all of which contain a conserved Cterminal domain, the BAG domain (Takayama et al., 1999) . There is little other homology between BAG-1 and BAG-3, including lack of the BAG-1L nuclear localization signal or the BAG-1 ubiquitin region. The BAG domain was shown by pull down experiments and functional assays to bind to and promote substrate release from both HSP-70 and HSC-70 (Stuart et al., 1998; Takayama et al., 1997 Takayama et al., , 1999 . Direct binding of BAG-1 to bcl-2 could not be demonstrated upon direct confrontation, however addition of ATP markedly enhanced BAG-1/bcl-2 binding, suggesting the requirement for an HSP-70 intermediate (Takayama et al., 1997) . HSP-70 and its constitutive form, HSC-70, are molecular chaperones activated by varied cellular stresses including heat shock, oxygen-free radicals, transition heavy metals, in¯ammation, ischemia, anti-neoplastics, oncogenes, and proto-oncogenes (Morimoto, 1998) . They bind ATP through an ATPase domain and have a separate substrate binding domain (Bukau and Horwich, 1998; Pilon and Schekman, 1999) . The site of Hsp70/Hsc70 binding to BAG-1 has been de®ned as the ATPase domain (Bukau and Horwich, 1998; Takayama et al., 1997) ; a 1 : 1 molar binding results in reduction in the refolding function of HSP-70 (Stuart et al., 1998) . While other functions for BAG-1 such as binding to and activating Raf-1 have been reported, no link between those functions and HSP-70 have been demonstrated. CAIR-1/BAG-3 was recently cloned also as bis (Lee et al., 1999) , in a protein interaction cloning procedure using bcl-2 as bait. Lee and coworkers demonstrated a weak antiapoptotic activity of transfected bis and further showed synergy when suboptimal doses of both bis and bcl-2 were transfected, simultaneously. They localized the site of interaction of bis to the BH1 domain of bcl-2.
Phospholipase C-g (PLC-g) regulates cytosolic free calcium concentration in response to transmembrane signal transduction, and has been linked to malignant transformation, invasive potential, and angiogenesis (Chang et al., 1997; Khoshyomn et al., 1999; Smith et al., 1998; Turner et al., 1996 Turner et al., , 1997 Yang et al., 1998) . Several investigators have demonstrated transforming capacity of both full length PLC-g and the isolated SH2-SH2-SH3 moiety (Bar-Sagi et al., 1993; Chang et al., 1997; Schlessinger, 1994; Smith et al., 1998) . Its link to calcium homeostasis, transmembrane signal transduction, and transforming potential made it a putative target protein in the calcium in¯ux stress model. We demonstrate that CAIR-1, which is increased in expression in CAItreated cells, is a partner protein for PLC-g, and forms a ternary complex with HSP-70. This provides a previously unknown link between transmembrane signaling and the HSP-70 system.
Results

Identification and cloning of CAIR-1/BAG-3
A2058 human melanoma cells were exposed chronically to continuing and escalating quantities of the calcium entry blocker, CAI. A subline previously shown to be sensitive in vitro and in vivo to the antiinvasive and anti-tumorigenic activity of CAI was used as the control for subtractive hybridization. A chemical cross-link solution hybridization protocol was used as described to minimize loss of low copy number transcripts (Hampson et al., 1992) and yielded 35 non-overlapping clones. A clone containing the 3' 1200 bp was upregulated by approximately threefold and was chosen for further analysis. CAIR-1, CAIstressed-1, was cloned as a 2.6 kb transcript encoding a 74 kDa protein (Figure 1a) , found by GenBank BLAST analysis to dier by 2 amino acids (227Q from a K; 237Q from an R) from BAG-3, a member of the bcl-2-associated athanogene family of bcl-2 binding proteins (Takayama et al., 1995 (Takayama et al., , 1999 . Genomic clones from chromosome 10q25 con®rm the CAIR-1 sequence. Northern analysis revealed a twofold net increase in expression of CAIR-1/BAG-3 in cells stressed by constant exposure to 10 ± 30 mM CAI (10 ± 30R, Figure 1b) but not in cells exposed to 10 mM CAI for 424 h (Figure 1c ). Domain analysis of CAIR-1/BAG-3 reveals the previously reported BAG region (Takayama et al., 1999) and WW domain, as well as seven putative protein kinase C (PKC) and ®ve putative CKII phosphorylation sites, multiple potential tyrosine phosphorylation sites, and a series of proline-rich PXXP repeats of the SH3 binding type (Pawson and Scott, 1997) . No genomic ampli®cation of CAIR-1/BAG-3 gene in the CAIstressed cells was demonstrated by Southern analysis or¯uorescent in situ hybridization (data not shown). Broad tissue expression of CAIR-1/BAG-3 was found in adult and embryonic tissues with lowest expression seen in hematopoietic tissues (Figure 1d ). Genomic conservation was limited to the higher eukaryotes by zoo blot (not shown, Bios, New Haven, CT, USA). Immunoprecipitation from A2058 cells followed by immunoblot with anti-peptide antibodies to CAIR-1/ BAG-3 recognized a 74 kDa protein which was increased in quantity in 20 mM CAI-stressed cells (Figure 1e ). No similar induction of CAIR-1/BAG-3 protein was observed in wild type A2058 or MDA-435 human breast cancer cells upon exposure to 10 mM CAI for up to 24 h (Figure 1f) , consistent with the lack of increased gene expression with acute CAI exposure.
CAIR-1/BAG-3 is phosphorylated in vivo CAIR-1/BAG-3 has not been demonstrated previously to be a phosphoprotein. Domain analysis of CAIR-1/BAG-3 indicated the presence of potential PKC and CKII phosphorylation sites, as well as putative tyrosine phosphorylation sites. In vivo phosphorylation demonstrated that CAIR-1/BAG-3 is phosphorylated in unstimulated wild type A2058 cells and unstimulated MDA-435 human breast cancer cells (Figure 2 ). No change in in vivo phosphorylation of CAIR-1/BAG-3 was found after cell treatment with PMA (100 ng/ml) for 30 min to stimulate endogenous PKC or 24 h to down-regulate PMA-sensitive classical and novel PKC isotypes (Figure 2a ) (Hata et al., 1993; Nishizuka, 1988) . Incubation with a broad spectrum inhibitor of all classes of PKC isotypes, d-ES (10 mg/ml for 2 h), markedly reduced CAIR-1/BAG-3 incorporation of 32 P-o-phosphate without eecting total cellular CAIR-1/BAG-3 (Figure 2b ). No tyrosine phosphorylation of CAIR-1 was demonstrated in unstimulated A2058 or MDA-435 human breast cancer cells. EGF treatment of MDA-435 cells, which did not eect the quantity of CAIR-1, resulted in tyrosine phosphorylation of CAIR-1/BAG-3 (Figure 2c ). CAIR-1/BAG-3 remained restricted to the cytosol upon EGF exposure. A small but statistically signi®cant eect of CAI (10 mM, 2 h) was seen on CAIR-1/BAG-3 basal phosphorylation in MDA-435 cells (87+4% of control, P50.05), along with the expected reduction in basal phosphorylation in response to d-ES (22+6% of control, P50.0008). An increase in in vivo incorporation of 32 P-ophosphate could be detected after 1 min exposure to EGF (100 ng/ml; P50.005, n=3; Figure 2d ).
In vivo binding of CAIR-1/BAG-3 to Hsp70/Hsc70 is increased by CAI exposure BAG-1 and BAG-3 have been shown through ex vivo binding experiments to bind to HSP-70 (BAG-1 only) and HSC-70 (both) through the newly described BAG domain (Takayama et al., 1999) . We demonstrate in CAIR-1/BAG-3 is a binding protein for latent PLC-g PLC-g was chosen as a putative CAIR-1/BAG-3 binding protein because of its potential involvement in the response to CAI stress, because its activation has been shown to be CAI-sensitive (Gusovsky et al., 1993) , and because it contains an SH3 domain to which the CAIR-1/BAG-3 PXXP regions could target. Unstimulated A2058 and MDA-435 cells were used initially to determine if CAIR-1 interacted with PLC-g independently of growth factor receptor induced interactions. Untreated cells were lysed under high stringency conditions (Buer A adjusted to 300 mM NaCl with added 0.1% Triton X-100 and 0.1% SDS) and subjected to immunoprecipitation with anti-CAIR-1/BAG-3 Ab 2 or Ab 8. Immunocomplexes were detected by immunoblot for PLC-g (Figure 4a ). Similar results were seen after precipitation with anti-PLC-g antibody and blotting with Ab2 or Ab8; approximately 3 ± 5% of total cellular PLC-g is bound to CAIR-1/ BAG-3 under basal conditions (data not shown). No association of PLC-b with CAIR-1/BAG-3 was found by coimmunoprecipitation in MDA-435 cells under standard or high stringency RIPA lysate conditions (Figure 4c ), indicating a selectivity of CAIR-1/BAG-3 for PLC-g.
EGF stimulation results in rapid dissociation of PLC-g from CAIR-1/BAG-3
We hypothesized that phosphorylation of CAIR-1/ BAG-3 would regulate its binding to PLC-g. EGF treatment of MDA-435 cells induced a dose-dependent reduction of the binding of PLC-g to CAIR-1/BAG-3 (Figure 5a ). The EGF dose response for this dissociation is log-linear (r 2 =0.99) with an EC 50 of 55 ng/ml. EGF induces a rapid loss of PLC-g binding from CAIR-1/BAG-3, with almost all loss of binding within the ®rst minute (Figure 5b ). The potential tyrosine phosphorylation sites in the BAG domain may regulate CAIR-1 Hsp70/Hsc70 complex formation. However, no signi®cant eect of EGF treatment (c) CAIR-1/BAG-3 is tyrosine phosphorylated upon EGF simulation. MDA-435 cells were exposed to EGF 50 ng/ ml for 10 min and then fractionated into cytosol and membrane components. Each fraction was subjected to immunoprecipitation with anti-phosphotyrosine, 4G10, and immunoblotted for CAIR-1/BAG-3. (d) CAI slightly but signi®cantly decreases and EGF increases in vivo phosphorylation of CAIR-1/BAG-3 in MDA-435 cells. Cells were prepared and immunoprecipitated as described. EGF does not induce CAIR-1 protein within a 5 min exposure (data not shown). Lane 1: DMSO control; 2: CAI 10 mM, 2 h; 3: d-ES 10 mg/ml, 2 h; 4: EGF 100 ng/ml, 1 min; 5: EGF 100 ng/ml, 5 min CAIR-1/BAG-3 binds to PLC-g and Hsp70/Hsc70 through separate and distinct domains CAIR-1/BAG-3 binds to the PLC-g SH3 domain PLC-g can interact with partner proteins through multiple domains, including its two SH2 domains and an SH3 domain (Koch et al., 1991; Pawson and Scott, 1997) . CAIR-1/BAG-3 was pulled down from unstimulated MDA-435 cell lysates by the GST-PLCg-SH3 domain but not the PLC-g-N-SH2 or C-SH2 domains (Figure 7a ). Treatment with EGF of the cells donating CAIR-1/BAG-3 did not alter CAIR-1/ BAG-3 binding to the PLC-g-SH3 domain, in contrast to what was observed with whole cell coimmunoprecipitation studies where EGF treatment reduced binding of CAIR-1/BAG-3 to PLC-g in whole cell lysates (Figure 7b) . No binding to SH2 domain constructs was seen after EGF stimulation. Hsp70/Hsc70 has been reported to bind to BAG-1 and BAG-3 through the BAG domain (Takayama et al., 1995 (Takayama et al., , 1997 (Takayama et al., , 1999 . No whole cell in vivo coprecipitation of PLC-g and Hsp70/Hsc70 was observed (data not shown). Reprobing of the PLC-g-SH3 domain binding blot for Hsp70/Hsc70 demonstrated that the PLC-g-SH3 construct pulled down Hsp70/Hsc70 from unstimulated and EGF-treated cell lysates equally (Figure 7c ).
PLC-g binds to the CAIR-1/BAG-3 PXXP domain
Pull down experiments were done using the PXXP4 region of CAIR-1/BAG-3, a region containing four dierent PXXP repeats (Figure 1 ) of SH3 binding type (Koch et al., 1991; Pawson and Scott, 1997) . This region does not include the BAG domain. This was done to determine if this region is the PLC-g binding site on CAIR-1/BAG-3 and thus the potential mechanism through which PLC-g associates with Hsp70/Hsc70. A second construct containing the three C-terminal PXXP repeats was also generated and tested. Both constructs bound PLC-g from unstimulated MDA-435 cell lysates (Figure 8a ) demonstrating that the PLC-g binding site on CAIR-1/BAG-3 is a functional PXXP SH3 binding site. In contrast to the PLC-g-SH3 experiments and consistent with the whole cell immunoprecipitation experiments, no or minimal binding of PLC-g from EGF-treated lysates to the CAIR-1/BAG-3 PXXP4 domain was found. Further, no Hsp70/Hsc70 could be detected in the GST-PXXP4 construct experiments (Figure 8b ). These data indicate a novel role for CAIR-1/BAG-3 as a binding partner of latent PLC-g, that PLC-g binding to the CAIR-1/BAG-3 SH3 binding domain is regulated by EGF treatment, and that PLC-g and Hsp70/Hsc70 bind CAIR-1/BAG-3 through dierent domains. Time course of release of PLC-g by CAIR-1/BAG-3. Cells were treated with EGF (100 ng/ml) from 0 ± 30 min and subjected to coimmunoprecipitation of CAIR-1/BAG-3 and PLC-g and for direct PLC-g immunoblot alone. (c) No signi®cant eect of EGF on Hsp70/Hsc70 binding to CAIR-1/BAG-3. Cells were exposed to EGF, 100 ng/ml for the indicated times, lysed, and subjected to immunoprecipitation with Ab2. The upper blot was probed for PLC-g and the lower blot for Hsp70/Hsc70. Controls include the rabbit IgG immunoprecipitation control (7, ®rst lane) and a simple Western blot (7, last lane)
Discussion
We demonstrate that CAIR-1/BAG-3 forms a ternary complex between latent PLC-g and Hsp70/Hsc70. This is the ®rst demonstration of a regulated crosstalk between Hsp70/Hsc70 and the EGFR-PLC-g signaling pathway. The lack of binding of Hsp70/Hsc70 to the CAIR-1/BAG-3 PXXP PLC-g binding domain suggests that PLC-g and Hsp70/Hsc70 interact with CAIR-1/ BAG-3 at distinct, non-overlapping locations on the CAIR-1/BAG-3 molecule. Partner protein binding of both CAIR-1/BAG-3 with PLC-g and CAIR-1/BAG-3 with Hsp70/Hsc70 is increased by CAI, the nonvoltage gated calcium in¯ux inhibitor used to stress cells for cloning of CAIR-1/BAG-3; d-ES, the PKC inhibitor, increased CAIR-1/BAG-3 binding to PLC-g but not to Hsp70/Hsc70. Release of PLC-g from CAIR-1/BAG-3 is stimulated by EGF treatment but abrogated by exposure to d-ES. CAIR-1/BAG-3 binds in vivo and in vitro to PLC-g from lysates from unstimulated cells but not from EGF treated cells whereas wild type PLC-g SH3 pulls CAIR-1/BAG-3 from both unstimulated and EGF-treated cells. This suggests that the PLC-g SH3 domain is a target site in the EGF receptor signaling pathway and argues against tyrosine phosphorylation of CAIR-1/BAG-3 as playing a role in the release of PLC-g after EGF treatment. These data are consistent with the concept that CAIR-1/BAG-3 is a stimulus to bring Hsp70/Hsc70 into proximity of PLC-g to allow or facilitate the change in the PLC-g SH3 domain and subsequent release from CAIR-1/BAG-3 (Figure 9 ). CAIR-1/BAG-3 is a protein containing multiple protein interaction motifs and phosphorylation sites (Figure 1) , in addition to a conserved BAG domain (Takayama et al., 1999) . We have focused on the PXXP region, a putative SH3 binding domain, and have demonstrated that this region binds the latent form of PLC-g. There is a rapid reduction in PLC-g binding to CAIR-1/BAG-3 seen after cellular EGF treatment. Release of PLC-g from CAIR-1/BAG-3 is rapid, nearly complete by 1 min. The kinetics of PLC-g phosphorylation as previously reported (Wahl et al., 1988; Yang et al., 1994 Yang et al., , 1998 and con®rmed by us in this model system shows the peak of phosphorylation occurring between 1 and 2 min. Maintenance of PLCg ± CAIR-1/BAG-3 binding is seen when a wild type PLC-g SH3 construct is used but a marked reduction in partner protein complex is observed when the CAIR-1/BAG-3 PXXP region is presented with lysates from EGF-treated cells. This implicates a change(s) in the conformation of the PLC-g SH3 domain is necessary for the process of CAIR-1/BAG-3 release of PLC-g upon EGF stimulation.
The BAG domain of CAIR-1/BAG-3 contains two tyrosine and three threonine residues that are not conserved from the BAG domain of BAG-1 (Takayama et al., 1999) . We demonstrate endogenous binding of CAIR-1/BAG-3 to Hsp70/Hsc70 and show an increase in complex formation when cells are stressed for 90 min by exposure to 10 mM CAI. Previous studies have shown a BAG-3 interaction with Hsp70/Hsc70 using BAG-GST pull down experiments, from BAG-3 expressed in intact cells, and using a *24 kDa recombinant BAG-3 fragment (Takayama et al., 1999) . These studies demonstrated that the 24 kDa BAG-3 fragment had an attenuated binding to Hsc70 in a BIA-Core assay and that Hsc70 dissociated more rapidly from the BAG-3 fragment BIA-Core chip than did the puri®ed BAG-1 or BAG-2 molecules. Our demonstration of endogenous binding of CAIR-1/ BAG-3 to Hsp70/Hsc70 con®rms that the interaction of CAIR-1/BAG-3 occurs in intact cells. The increase seen after CAI exposure indicates that this protein interaction may be important to the cellular response to stress. It is possible that the ternary complex of CAIR-1/BAG-3, PLC-g, and Hsp70/Hsc70 found in unstimulated cells is present so that Hsp70/Hsc70 may assist in an EGF-stimulated PLC-g SH3 conformational change resulting in release of PLC-g from CAIR-1/BAG-3.
A binding protein for latent PLC-g has not been recognized previously. The function of activated PLC-g is to hydrolyze phosphatidylinositol 4, 5-bisphosphate to inositol 1, 4, 5-trisphosphate and diacylglycerol, mediators of release of intracellular calcium and calcium in¯ux, and activation of protein kinase C, respectively. We ®nd that abrogation of calcium in¯ux with CAI and of PKC activity with d-erythrosphingosine augments CAIR-1/BAG-3 ± PLC-g complex formation and that d-erythrosphin- Buer A lysates from cells treated with EGF (100 ng/ml, 1 min) were subjected to pull down experiments as described and probed for CAIR-1/BAG-3 (b) or Hsp70/ Hsc70 (c) gosine can overcome the release of PLC-g stimulated by EGF. These regulatory pathways may thus have a feedback mechanism to limit the availability of PLC-g for activation. That d-erythrosphingosine also regulates in vivo phosphorylation of CAIR-1/BAG-3 suggests that there may be an internal regulatory site in CAIR-1/BAG-3. Studies have shown that Ser/ Thr phosphorylation in the vicinity of an SH3 binding domain can regulate that binding (Chen et al., 1997; Hu and Bowtell, 1996; Pawson and Scott, 1997) . Published examples show that SOS phosphorylation prevented or reduced its binding to Grb2, yielding the hypothesis that phosphorylation of Sos1 alters recognition or anity of the Grb2 N-SH3 domain. Our observations indicate that a phosphorylation event may increase binding in an opposite paradigm to that presented for the Grb2/SOS interaction.
Xenobiotics and anti-cancer therapeutics have been well documented as cell stress inducers. We demonstrate that continuous long term exposure to CAI, an inhibitor of nonvoltage-gated calcium in¯ux and an anti-cancer agent in clinical trials, stimulates an increase in expression of CAIR-1/BAG-3, a binding partner of both latent PLC-g and Hsp70/Hsc70. The demonstration of a ternary complex and an obligate change in the PLC-g SH3 domain required for release of PLC-g from CAIR-1/BAG-3 upon growth factor stimulation implicates Hsp70/Hsc70 in the release process. Hsp70/Hsc70 is not released from CAIR-1/ BAG-3 by growth factor treatment. These data suggest that regulation of activation of PLC-g may begin with Figure 8 PLC-g binds to the PXXP domain of CAIR-1/BAG-3. Buer A whole cell lysates were used for CAIR-1/BAG-3 PXXP pull down experiments. Constructs containing the PXXP3 or PXXP4 region of CAIR-1/BAG-3 were subjected to binding with unstimulated or EGF-treated (100 ng/ml, 1 min) whole cell lysates. Complexes were probed for PLC-g (a) or Hsp70/Hsc70 (b) Figure 9 Model of proposed CAIR-1/BAG-3 protein binding interactions its docking site and not with growth factor receptor activation and phosphorylation.
Materials and methods
Materials
cDNA synthesis kits and protein A agarose beads were obtained from Gibco/BRL (Gaithersburg, MD, USA). The labeling kit was from Amersham (Arlington Heights, IL, USA) and all radionuclides from NEN-Dupont (Boston, MA, USA). Precast polyacrylamide gels were from Novex (San Diego, CA, USA). The multiple tissue Northern blot was from Clontech (Palo Alto, CA, USA). Anti-phosphotyrosine monoclonal antibody (4G10), anti-PLC-g, anti-PLC-b antibodies, and GST-PLC-g-N-SH2, GST-PLC-g-C-SH2 and GST-PLC-g-SH3 were obtained from UBI (Lake Placid, NY, USA). Anti-Hsp70/Hsc70 was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). pGEX 2T and 4T3 vectors were from Pharmacia Biotechnology (Piscataway, NJ, USA). The BCA protein assay, protein A/G beads, secondary antibodies, and ECL kits were purchased from Pierce (Rockford, IL, USA). EGF was from Collaborative Biomedical Products (Bedford, MA, USA) and phosphate-free media from Bio¯uids (Rockville, MD, USA). All other products were of molecular or analytical grade.
Lysate production
Total cell lysates were prepared from subcon¯uent tumor cells using modi®ed RIPA buer A (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 10 mg/ml aprotinin, 1 mM PMSF, 10 mg/ml leupeptin, 2 mM Na 3 VO 4 , 4 mM EDTA, 10 mM NaF, 10 mM Na pyrophosphate, 1% NP-40 and 0.1% sodium deoxycholate (20)) or a high stringency RIPA buer B (buer A adjusted to 300 mM NaCl, plus 0.1% Triton X-100 and 0.1% SDS) on ice, followed by sonication. Fractionated lysates were prepared by hypotonic lysis (Buer C: 25 mM Tris-Hcl pH 7.5, 255 mM sucrose, 4 mM EDTA, 400 mM Na 3 VO 4 , 100 mM NaF, 10 mM Na pyrophosphate, 1 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml aprotinin). These lysates were spun at 500 g for 15 min at 48C to pellet the nuclei. The supernatant was centrifuged at 100 000 g for 30 min at 48C yielding the cytosolic fraction. The high spin pellet was incubated in buer C with added 1% Triton X-100 and 1% sodium deoxycholate for 30 min on ice to solubilize the membrane components. The supernate of a 10 min centrifugation at 800 g (48C) constituted the membrane fraction. All lysates were aliquoted and subjected to no greater than 1 freeze/thaw cycle.
Preparation of anti-peptide antibodies, immunoprecipitation, and immunoblot
Polyclonal rabbit antisera were raised against keyhole limpet hemocyanin (KLH)-conjugated CAIR-1 peptides 2 (SSPKSV-ATEERAAPS) and 8 (DKGKKNAGNAEDPHT). Antipeptide antibodies were puri®ed over peptide-conjugated Agel-10 columns and titered for activity by immunoblot analysis. Speci®city of Ab2 and Ab8 in immunoblot and immunoprecipitation was demonstrated by peptide competition assays using cognate peptide and, as a control, the alternate peptide. For immunoprecipitation, equal quantities of lysate protein (range: 200 ± 1000 mg) were precleared with protein A or A/G beads and control IgG, then immunoprecipitated with control IgG or speci®c antibody for 2 h at 48C. Immunocomplexes were captured with protein A or A/G beads for 2 h at 48C and then washed ®ve times with lysis buer (A or B) as indicated. Protein lysate or immunoprecipitates were subjected to reducing gel electrophoresis followed by immunoblotting. Bands were detected with ECL following standard protocols. Protein partner binding was tested by co-immunoprecipitation. Buer B lysates were pre-cleared with protein A/G beads incubated with control rabbit IgG, after which the supernatant was immunoprecipitated either with control antibody (puri®ed rabbit IgG) or anti-CAIR-1 Ab2 or Ab8. Immunocomplexes were captured, washed ®ve times with buer B, and assayed as above. Where indicated, cell monolayers were exposed to CAI (10 mM for 90 min), d-erythrosphingosine (d-ES, 10 mg/ml for 2 h) or EGF prior to lysis. Unless otherwise indicated, results shown are representative of n53 replicate experiments.
In vivo phosphorylation
Cells were grown to subcon¯uence and washed into phosphate-free, serum-free media for 4 h. 32 P-o-phosphate (62.5 mCi/ml) was added in fresh phosphate-and serum-free media and cells were incubated for a further 2 h and then washed with iced PBS. Cells were lysed with buer A as described above. Samples were precleared with protein A beads and then subjected to immunoprecipitation and electrophoresis, then gels were exposed to ®lm. Where indicated, cells were treated with d-ES (10 mg/ml) or CAI (10 mM) during the 32 P-o-phosphate incubation for the 2 h immediately prior to lysis, or incubated with 100 mg/ml phorbol 12-myristate 13-acetate (PMA) for either 30 min or 24 h prior to lysis. EGF 100 ng/ml was used for 1 or 5 min prior to lysis. Results are representative of n=3 experiments.
GST pull down experiments
Commercially available prebound GST fusions containing the N-or C-SH2 domains of PLC-g (25 mg) were subjected to protein binding overnight using Buer A MDA-435 cell lysates (500 mg protein). Bound complexes were washed ®ve times with Buer A, resuspended in sample buer and subjected to gel electrophoresis and immunoblotting with Ab2. Blots were acid-stripped and then probed with antiHsp70/Hsc70. Identical results were obtained using 25 mg of prebound GST-PLC-g constructs were incubated with 30 mg lysates in 400 ml binding buer (20 mM Tris pH 7.5, 100 mM NaCl, 2 mM EDTA, 0.1% NP-40, 2 mM DTT, 0.05% BSA and 5% glycerol). Complexes were rocked at 48C for 2 h then washed ®ve times in 1 ml TENNS buer (2.5 mM Tris pH 7.5, 2.5 mM EDTA, 250 mM NaCl, 1% NP-40 and 2.5% sucrose) (Takayama et al., 1995) and resuspended in sample buer, subjected to electrophoresis then immunoblotted.
The CAIR-1/BAG-3 region containing the C terminal 3 or all 4 PXXP putative SH3 binding domains ( Figure 1) were ampli®ed by PCR (5' primer for PXXP4: CTG GAT CCC CTG AAA ACA AAC CAG AA; 5' primer for PXXP3: GGA TCC ATC CGC AA GAG GTG GAT; 3' primer for both: CTA GAA TTC TCA CAC TTT CAG CAC TCC TGG; PCR conditions: 948C61 min; 548C645 s; 728C645 s, 30 cycles) and subcloned into PGEX-2T (PXXP3) or PGEX-4T3 (PXXP4). Clone sequences were veri®ed, then bacterial fusion protein from PXXP or control null vector-transduced clones were produced according to manufacturer's instructions. Fusion proteins were immobilized on glutathione-Sepharose 4B beads preblocked in 0.5% nonfat milk and 0.05% BSA (Takayama et al., 1995) . Preblocked beads were washed three times with PBScontaining protease inhibitors (PBS+PI; 0.001% aprotinin, 0.001% leupeptin, 10 mM Na pyrophosphate, 4 mM EDTA and 1 mM PMSF). Beads (100 ml) were bound with GST or GST-PXXP fusion proteins in PBS+PI at 48C for 2 h. Bound beads (25 ml) were incubated with 30 mg MDA 435 cell lysates in 400 ml binding buer at 48C for 2 h, then washed ®ve times in TENNS buer. The beads were resuspended in sample buer and analysed by electrophoresis and immunoblotting for PLC-g. The blot was acid-stripped and reprobed for Hsp70/Hsc70. Results are representative of n53 replicate experiments.
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Statistical analysis
Where indicated Student's t-test analysis was done using Microsoft Excel (Seattle, WA, USA). All reported P values are 2-tailed.
Abbreviations CAI, carboxyamido-triazole; EGF, epidermal growth factor; PMA, phorbol 12-myristate 13-acetate; d-ES, derythrosphingosine.
